APA (7th ed.) Citation

P, T., T, L., ER, O., T, R., MK, D., A, P., . . . AG, W. (2026). Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial. JAMA oncology. https://doi.org/10.1001/jamaoncol.2026.2023

Chicago Style (17th ed.) Citation

P, Tarantino, et al. "Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial." JAMA Oncology 2026. https://doi.org/10.1001/jamaoncol.2026.2023.

MLA (9th ed.) Citation

P, Tarantino, et al. "Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial." JAMA Oncology, 2026, https://doi.org/10.1001/jamaoncol.2026.2023.